PBYI
PUMA BIOTECHNOLOGY, INC.Company Information
- Company Name
- PUMA BIOTECHNOLOGY, INC.
- CIK
- CIK0001401667
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PBYI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PBYI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-14
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 257,995
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,093,612
- Shares outstanding
- 50,939,946
- Ownership
- 68.89%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 11.58%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 37 | 36 | 30 | 54 | 55 | 63 | 69 | 67 | 67 | 77 | 85 | 82 | ||||||
| Marketable Securities Current | 57 | 65 | 68 | 41 | 41 | 30 | 32 | 29 | 30 | 30 | 11 | 3 | ||||||
| Accounts Receivable Net Current | 34 | 26 | 54 | 34 | 26 | 25 | 32 | 55 | 28 | 25 | 48 | 29 | ||||||
| Inventory Net | 13 | 9 | 6 | 9 | 9 | 9 | 9 | 3 | 9 | 7 | 7 | 6 | ||||||
| Prepaid Expense Current | 4 | 3 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | ||||||
| Restricted Cash Current | 0 | 2 | 2 | 2 | 2 | - | 0 | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | ||||||
| Assets Current | 145 | 142 | 163 | 144 | 137 | 133 | 148 | 157 | 138 | 143 | 156 | 125 | ||||||
| Operating Lease Right Of Use Asset | 4 | 5 | 5 | 6 | 3 | 4 | 5 | 5 | 6 | 7 | 8 | 9 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Including Goodwill | 37 | 39 | 41 | 44 | 46 | 49 | 51 | 54 | 56 | 58 | 61 | 63 | ||||||
| Restricted Cash Noncurrent | - | - | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | ||||||
| Deferred Income Tax Assets Net | 4 | 4 | 4 | 7 | 7 | 7 | 7 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Noncurrent | 3 | 3 | 3 | 2 | 2 | 2 | 0 | 2 | 2 | 3 | 3 | 3 | ||||||
| Assets | 193 | 193 | 216 | 203 | 195 | 196 | 213 | 221 | 205 | 214 | 231 | 204 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 8 | 5 | 6 | 5 | 6 | 6 | 8 | 14 | 9 | 7 | 5 | ||||||
| Accrued Liabilities Current | 45 | 38 | 50 | 37 | 32 | 27 | 37 | 51 | 39 | 38 | 53 | 34 | ||||||
| Operating Lease Liability Current | 0 | 0 | 1 | 2 | 4 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | ||||||
| Long Term Debt Current | 0 | 11 | 23 | 34 | 34 | 45 | 45 | 45 | 45 | 45 | 34 | 23 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 50 | 60 | 81 | 83 | 79 | 87 | 96 | 110 | 104 | 98 | 99 | 67 | ||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 5 | 5 | 0 | 0 | 1 | 3 | 4 | 6 | 7 | 8 | ||||||
| Liabilities | 54 | 64 | 86 | 88 | 90 | 99 | 121 | 150 | 156 | 163 | 177 | 165 | ||||||
Stockholders Equity | ||||||||||||||||||
| Long Term Debt Noncurrent | - | 0 | 0 | 0 | 11 | 11 | 22 | 33 | 44 | 55 | 66 | 77 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,418 | 1,416 | 1,414 | 1,412 | 1,411 | 1,409 | 1,407 | 1,405 | 1,403 | 1,401 | 1,399 | 1,396 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,279 | -1,288 | -1,284 | -1,297 | -1,306 | -1,312 | -1,315 | -1,334 | -1,355 | -1,350 | -1,345 | -1,357 | ||||||
| Stockholders Equity | 139 | 128 | 130 | 115 | 105 | 97 | 92 | 71 | 49 | 51 | 53 | 39 | ||||||
| Liabilities And Stockholders Equity | 193 | 193 | 216 | 203 | 195 | 196 | 213 | 221 | 205 | 214 | 231 | 204 | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 51 | 51 | 50 | 50 | 50 | 50 | 49 | 49 | 48 | 48 | 48 | 48 | ||||||
| Shares Outstanding | 51 | 51 | 50 | 50 | 50 | 50 | 49 | 49 | 48 | 48 | 48 | 48 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPUMA BIOTECHNOLOGY, INC. (PBYI) — SEC Financial Statements & Analysis
PUMA BIOTECHNOLOGY, INC. (PBYI) is a pharmaceutical preparations company, incorporated in DE. PUMA BIOTECHNOLOGY, INC. trades on Nasdaq as: PBYI. PUMA BIOTECHNOLOGY, INC. (PBYI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, PUMA BIOTECHNOLOGY, INC. carries a market cap of $413.12M, a P/E ratio of 15.46x, a P/B ratio of 2.98x, a P/S ratio of 1.79x, an enterprise value of $376.59M, and an EV/EBITDA multiple of 9.20x. On profitability, it posts a gross margin of 74.83%, an operating margin of 13.16%, a net margin of 11.55%, a Return on Equity (ROE) of 21.97%, a Return on Assets (ROA) of 13.78%, and a Return on Invested Capital (ROIC) of 28.36%. Per share, it reports EPS of $0.52, diluted EPS of $0.51, free cash flow per share of $0.81, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -2.86% year-over-year, net income growth of -44.86% year-over-year, and EPS growth of -46.20% year-over-year. On the balance sheet, it maintains a current ratio of 2.91x, a quick ratio of 2.57x, working capital of $95.25M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, an interest coverage ratio of 8.65x, free cash flow of $41.09M (TTM), and net debt of $-36.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $413.12M
- P/E TTM
- 15.46x
- EPS TTM
- $0.52
- P/B TTM
- 2.98x
- ROE TTM
- 21.97%
- ROA TTM
- 13.78%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $41.09M
- Net Revenue TTM Growth 1Y
- -2.86%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PUMA BIOTECHNOLOGY, INC. in?
PUMA BIOTECHNOLOGY, INC. (PBYI) operates in the Pharmaceutical Preparations industry.
What exchange does PBYI trade on?
PUMA BIOTECHNOLOGY, INC. (PBYI) trades on the Nasdaq.
Where is PUMA BIOTECHNOLOGY, INC. incorporated?
PUMA BIOTECHNOLOGY, INC. is incorporated in DE.
When was PUMA BIOTECHNOLOGY, INC. (PBYI)'s most recent SEC filing?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is PBYI's market cap?
PUMA BIOTECHNOLOGY, INC. (PBYI) has a market capitalization of $413.12M as of 2026-06-30.
What is PBYI's P/E ratio?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month P/E ratio is 15.46x as of 2026-06-30.
What is PBYI's EPS (earnings per share)?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month EPS is $0.52 as of 2026-06-30.
What is PBYI's ROE (return on equity)?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month Return on Equity (ROE) is 21.97% as of 2026-06-30.
What is PBYI's ROA (return on assets)?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month Return on Assets (ROA) is 13.78% as of 2026-06-30.
What is PBYI's ROIC (return on invested capital)?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month Return on Invested Capital (ROIC) is 28.36% as of 2026-06-30.
What is PBYI's EV/EBITDA?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s trailing twelve month EV/EBITDA is 9.20x as of 2026-06-30.